Hematopoietic stem cells (HSCs) originate within the aortic-gonado-mesonephros (AGM) region of the midgestation embryo, but the cell type responsible for their emergence is unknown since critical hematopoietic factors are expressed in both the AGM endothelium and its underlying mesenchyme. Here we employ a temporally restricted genetic tracing strategy to selectively label the endothelium, and separately its underlying mesenchyme, during AGM development. Lineage tracing endothelium, via an inducible VE-cadherin Cre line, reveals that the endothelium is capable of HSC emergence. The endothelial progeny migrate to the fetal liver, and later to the bone marrow, and are capable of expansion, selfrenewal, and multilineage hematopoietic differentiation. HSC capacity is exclusively endothelial, as ex vivo analyses demonstrate lack of VE-cadherin Cre induction in circulating and fetal liver hematopoietic populations. Moreover, AGM mesenchyme, as selectively traced via a myocardin Cre line, is incapable of hematopoiesis. Our genetic tracing strategy therefore reveals an endothelial origin of HSCs.
INTRODUCTION
The first site of mammalian intraembryonic hematopoiesis consists of the dorsal aorta during a developmental period when it is flanked by the gonado-mesonephric columns (the AGM region) Medvinsky and Dzierzak, 1996) . Within the AGM at E10.5-11.5, hematopoietic cells can be seen attached to the aorta and have been referred to as ''budding'' from this region (Garcia-Porrero et al., 1995; Jaffredo et al., 1998) . Whether these ''budding'' hematopoietic cells arise from endothelium or its underlying mesenchyme is still a matter of controversy (North et al., 1999; de Bruijn et al., 2002; Bertrand et al., 2005) . The difficulty lies in the fact that the two regions, from a technical standpoint, are not amenable to physical separation, and both are noted to express signaling molecules and transcription factors critical for hematopoiesis (North et al., 2002; Bertrand et al., 2005) . In addition, while the AGM is a site of HSC emergence, it is unable to support hematopoietic differentiation (Godin et al., 1999) , an attractive feature that may enable its application in vitro, once the specific cell type and mechanisms of HSC emergence are delineated.
The AGM region has been shown through numerous assays to generate hematopoietic stem cells (HSCs), which are capable of multilineage long-term reconstitution of irradiated hosts (Medvinsky and Dzierzak, 1996; Cumano et al., 2001) . However, many of these studies required ex vivo manipulations that separate tissues from the circulation and their physiological milieu (Medvinsky and Dzierzak, 1996; Cumano et al., 2001) . The majority of analyses include either the entire AGM or its dissected subregions without restriction to a specified cell type Medvinsky and Dzierzak, 1996; Cumano et al., 2001) . The complexity of investigating HSC emergence in vivo is that once circulation is established, it is difficult to determine which embryonic sites contribute to later hematopoiesis and which cell types are necessary and sufficient for the ontogeny of HSCs.
VE-cadherin, a cell-adhesion molecule with restricted endothelial expression (Breier et al., 1996; Dejana et al., 1999) , has been implicated as a marker for hematopoietic cells arising from the AGM (Nishikawa et al., 1998; Fraser et al., 2002; Fraser et al., 2003) . As many cell-surface markers are shared between hematopoietic cells and endothelium, it has been suggested that AGM HSCs are endothelial derived (Jaffredo et al., 1998; de Bruijn et al., 2002; North et al., 2002; Sugiyama et al., 2003) . VE-cadherin protein was also shown to identify HSC populations within the circulation and fetal liver (Kim et al., 2005; Taoudi et al., 2005) . Whether this protein expression is a result of a ''carryover'' effect from potential endothelial progenitors or the outcome of active VE-cadherin gene expression remains to be clarified.
The HSCs of the AGM have been demonstrated to be incapable of in situ hematopoietic differentiation (Godin et al., 1999) . Therefore, it has been postulated that AGM cells migrate to the fetal liver for terminal differentiation, with final residence in the adult bone marrow (Delassus and Cumano, 1996) . The proof of migration from one particular site to another has been, up to this point, difficult to establish. The goal of this study was to utilize inducible Cre/lox technology to label particular populations, during a narrow developmental window, and lineage trace AGM endothelial and mesenchymal progeny to their intermediate and final destinations as well as to determine the cell type responsible for HSC emergence.
RESULTS

VE-Cadherin Lineage Labels the Vascular and Hematopoietic AGM Population
As studies have demonstrated the expression of VE-cadherin within the endothelium and HSCs of the AGM (North et al., 2002; Fraser et al., 2003) , we investigated whether these cells can be labeled and traced using a constitutive VE-cadherin Cre mouse crossed to a ROSA26R (R26R) Cre reporter line (Soriano, 1999) . As noted in Figure 1A , the constitutive VEcadherin Cre/R26R line exhibits b-galactosidase (b-gal) labeling of the developing vascular system at E10.5-11. At this time, the AGM region ( Figures 1B and 1C ) reveals preferential labeling of the ventral wall of the dorsal aortic endothelium, an area noted for HSC emergence North et al., 2002; Taoudi and Medvinsky, 2007) . In addition, cells similar to the previously described ''budding'' HSCs are also labeled ( Figure 1C , arrows). During peak fetal liver hematopoietic capacity, there exists a stark contrast of VE-cadherin protein expression, which appears predominantly vascular ( Figure 1D ), to the b-gal-labeled (VE-cadherin lineage) populations of both hematopoietic and endothelial cells ( Figure 1E ). This discrepancy between VEcadherin protein expression and b-gal labeling is due to the latter depicting a historical population of hematopoietic progeny, which were traced from a VE-cadherin+ cell type. The progeny can also be detected in the adult bone marrow, as demonstrated in Figure 1F . When quantified by FACS analysis of b-gal expression, the VE-cadherin progeny constitute approximately 20%-40% of the fetal liver population and average 52% (±5% SEM) of the adult bone marrow ( Figure 1G ). The demonstration of labeled cells within definitive hematopoietic sites, in excess of reported VE-cadherin protein expression at these sites (Quirici et al., 2001; Kim et al., 2005; Taoudi et al., 2005) , points to the ability of earlier VE-cadherin+ cells to give rise to definitive hematopoietic progeny. Additional support for this conclusion is the fact that VE-cadherin progeny in the fetal liver population express stem markers typical of this developmental time point, while the adult bone marrow population expresses markers of all hematopoietic lineages, including stem markers ( Figure 1H ). While the aforementioned data suggest that the VE-cadherin AGM population is capable of definitive adult hematopoiesis, it cannot exclude the potential contribution of extraembryonic, yolk sac-derived cells. In fact, it has been demonstrated in the VE-cadherin Cre mouse , and other hemangioblast studies (Wang et al., 2004; Yokomizo et al., 2007) , that the early yolk sac hematopoietic population includes a significant subset of VE-cadherin progeny (see Figure S1A available online). In addition, while there has been longstanding debate as to whether early yolk sac cells are capable of definitive adult hematopoiesis, recent data support this possibility (Samokhvalov et al., 2007) . Thus, to avoid labeling early yolk sac populations and investigate the VE-cadherin AGM population, an inducible fate map with time-restricted labeling was utilized.
Notably, VE-cadherin Cre does not label all hematopoietic cells, as demonstrated in the fetal liver and adult bone marrow ( Figures 1E and 1F ). While AGM hematopoietic cells are labeled in this Cre line, later hematopoietic sites clearly contain an unlabeled population, which may suggest a nonvascular/non-VEcadherin+ hematopoietic source. The VE-cadherin null mouse exhibits lethality by E9.5-10, with absence of intraembryonic hematopoiesis (Carmeliet et al., 1999; Gory-Faure et al., 1999) , but with preservation of some yolk sac hematopoiesis (Rampon and Huber, 2003) . Examination of the VE-cadherin null yolk sac demonstrates disorganized vasculature and accumulation of hematopoietic cells within underdeveloped vascular lumens ( Figure S1B ). It is unclear whether the yolk sac cells in the VE-cadherin null mouse represent progeny from primitive or disorganized VE-cadherin null vasculature or rather that the cells do not require VE-cadherin. If the latter is true, it may account for the unlabeled population in the VE-cadherin Cre fetal liver and adult bone marrow. Another possibility is that while upstream intronic sequences of the VE-cadherin promoter are known to enhance endothelial expression of VE-cadherin (Hisatsune et al., 2005) , the observed unlabeled population may be a reflection of the promoter used.
Inducible VE-Cadherin Cre Selectively Labels AGM Endothelium and Midgestation Hematopoiesis To obtain restricted labeling of VE-cadherin progeny in the AGM from E10-11.5, when most hematopoietic budding is observed (Garcia-Porrero et al., 1995) , a tamoxifen-inducible VE-cadherin Cre line was crossed to the R26R line (Soriano, 1999) . Tamoxifen is thought to be available for Cre activation throughout the first 48 hr after injection (Nakamura et al., 2006) . However, assessment of tamoxifen metabolites in serum indicates that minimally active levels remain up to 72 hr postdose (Figure S2, Supplemental Text and Supplemental Experimental Procedures) . Therefore, tamoxifen induction of Cre expression was investigated during two separate time points to reveal the optimal period for AGM induction (Figure 2 ). In addition to the dorsal aortic endothelium, the vitelline and umbilical arteries also exhibit clusters of hematopoietic cells, prior to the AGM (Garcia-Porrero et al., 1995; North et al., 1999; de Bruijn et al., 2000) . These arteries are preferentially labeled when induction is triggered by tamoxifen injection at E8.5 ( Figure 2A ). The lag in aortic labeling is also seen in the constitutive VE-cadherin Cre line where the dorsal aortic endothelium is only partially labeled by E9.5 . Induction at E9.5 demonstrates significantly reduced labeling of the vitelline and umbilical artery during their period of hematopoiesis and instead primarily labels the AGM endothelium and its associated hematopoietic cells ( Figure 2B ). However, the umbilical and vitelline vessels are eventually labeled at E11.5 as the endothelial population expands (data not shown). The increased vascular labeling at E11.5 after E9.5 induction, as compared to E8.5 (Figures 2A and 2B, middle panels), is likely due to a developmental increase in vascular VE-cadherin Cre expression during this period.
Thus, timed induction of Cre expression was carried out at E9.5, allowing the tamoxifen ''window'' to span from E9.5 to E12.5, encompassing the period of AGM hematopoietic activity ( Figure 3A) , while bypassing the period of VE-cadherin expression in early yolk sac progenitors. A single dose of tamoxifen (1 mg) was administered via intraperitoneal injection (i.p.) into pregnant mothers at E9.5, and embryos were evaluated at E10.5, E11.5, and E14.5, as well as at adult stages. At E10.5, very little recombination was noted, as evidenced by b-gal labeling ( Figure 2B ). By E11.5, the inducible system labeled the dorsal aortic endothelium and ''budding'' hematopoietic cells, as shown in Figure 3Ca . Although the level of recombination did not match that of the constitutive system ( Figure 3B ), it was sufficient to allow lineage tracing to the fetal liver at E14.5 ( Figure 3Cb ). Thus, from the one dose of tamoxifen we were able to demonstrate recombination (via reporter activity) in the AGM endothelium by E11.5, with subsequent reporter expression in attached hematopoietic cells ( Figure 3Ca ) and later expansion and migration of the progeny to the fetal liver ( Figure 3Cb ).
VE-Cadherin Endothelial Population Gives Rise to Definitive Adult Hematopoiesis
The definition of a HSC includes its capacity to self-renew, to give rise to all hematopoietic lineages, and to reconstitute irradiated adult host bone marrow for more than 8 months. The inducible system allows HSC tracking in vivo and thus avoids the removal of cells from their milieu. A small cell population was labeled during a finite embryonic window (single embryonic injection at E9.5) and followed, in vivo, into adulthood (up to 13 months postnatal age). The bone marrow from this cohort demonstrated reporter-labeled bone marrow cells constituting anywhere from 2%-24% of total bone marrow cells ( Figure 4A ). The wide range is likely due to inherent tamoxifen dose variation among littermates ( Figure S2D ). Nonetheless, a large number of offspring (12 out of 13) demonstrated labeled bone marrow cells exhibiting cell-surface markers of all hematopoietic lineages as well as stem cell markers ( Figure 4B , Figure S3 ). In addition, a subset of animals (n = 4), were evaluated for the presence of VE-cadherin progenitors in the spleen and thymus, where labeled cells were also noted (Figure 4, panels) . Endothelial cells that were labeled in the embryo also demonstrate progeny in adult vessels (Figure 4 , bottom panels). The fact that cells genetically marked at midgestation have progeny detected as late as 1 year postnatally strongly suggests a stem population. Furthermore, the expression of stem markers Sca-1+/c-kit+ within this late population, as well as markers identifying all hematopoietic lineages, demonstrates that the induced VE-cadherin endothelial population is autonomously capable of definitive hematopoiesis. In contrast to earlier studies, these data physiologically demonstrate, in vivo, that a restricted VE-cadherin population from the endothelium and its associated hematopoietic cells produce progeny that give rise to adult hematopoiesis.
Fetal Liver VE-Cadherin Population Is Migratory and Does Not Originate In Situ
Recent studies have indicated that fetal liver HSCs express VEcadherin protein (Kim et al., 2005; Taoudi et al., 2005) . Thus, we investigated whether the inducible system inadvertently labels the fetal liver VE-cadherin population during the active tamoxifen window (E9.5-12.5). To address this question, fetal liver cells were induced ex vivo for 24 hr as organ cultures at E10.5, E11.5, and E12.5. Following 4-hydroxytamoxifen (4OHT) induction, a subset of fetal livers was cultured in methylcellulose hematopoietic colony assays for 1 week ( Figure 5A ). Cre recombinase induction was measured by both b-gal activity and FACS analysis of the CD45+ population using a R26R EYFP line (Srinivas et al., 2001) . In vitro 4OHT induction did not label hematopoietic cells within the fetal liver during any of the time points investigated ( Figure 5C ). Instead, labeled vascular structures were noted that were unable to give rise to hematopoietic cells ( Figure 5C , arrows). This differs from constitutive VE-cadherin Cre/R26R livers, in which labeled hematopoietic cells were capable of expanding, both in the organ culture and methylcellulose ( Figure 5D ). The lack of hematopoietic activity in the tamoxifen-treated fetal livers also differed significantly from the AGM endothelial induction and hematopoietic cell labeling ( Figure 5B ). To further verify the results of the in vitro system, embryonic lung was also cultured and resulted in exclusively vascular labeling ( Figure S4A ). Also of note is the diminished vascular labeling in the induced fetal liver with increasing age ( Figure 5C ). To ensure this was not due to artificially decreased physiologic VE-cadherin gene expression in vitro, we compared dissected to cultured fetal livers and noted a slight increase in VE-cadherin expression within the cultured group ( Figure S4B) . Thus, the labeled hematopoietic population observed within the fetal liver, in vivo, is a migratory population likely originating from the AGM. The data are reconciled with previous reports of HSC VE-cadherin protein expression by understanding that the system reflects VE-cadherin promoter activity. Therefore, it is quite possible that while the VE-cadherin promoter is no longer active in the early fetal liver hematopoietic population, the protein may continue to be expressed as a result of promoter activation in the AGM endothelium. However, shortly thereafter, the surface (E) Peripheral blood was pooled at E11.0 and induced in vitro for 24 hr in suspension. Cells were then analyzed for EYFP expression within the CD45+ population. Alternatively, the corresponding AGMs were induced for 24 hr in organ culture, pooled, and analyzed for EYFP expression within hematopoietic (CD45+) and endothelial (PECAM+ CD45À) compartments. Only the AGM, with endothelial induction, was capable of producing labeled hematopoietic cells. expression of VE-cadherin on fetal liver HSCs is noted to be significantly reduced (Kim et al., 2005; Taoudi et al., 2005) .
Circulating VE-Cadherin Population Is Derived from the Endothelium Much like the fetal liver, circulating cells have also been shown to express VE-cadherin protein at midgestation (Taoudi et al., 2005) . To investigate whether cells in the circulation could be induced to express VE-cadherin Cre and thus alter the interpretation of the endothelial tracing results, we pooled E11.0 peripheral blood and cultured the cells overnight in suspension with 4OHT ( Figure 5E ). Pooled AGMs from the same embryos were also 4OHT treated overnight in organ culture ( Figure 5E ). Notably, only the AGM endothelium (CD45-PECAM-1+) was labeled and able to produce reporter positive hematopoietic cells (CD45+); see Figure 5E . Also of interest is that the percentage of labeled endothelium (4.81% in Figure 5E ) mirrors that of the hematopoietic population after 1 week of methylcellulose culture (4.27% in Figure 5B ). This suggests that the labeled hematopoietic population capable of self-renewal and expansion is proportional to the induction of the endothelial population. In vitro induction of peripheral blood at ages E10.5 and E12.5 also resulted in lack of recombination within the hematopoietic population (data not shown). Lastly, when E10.5 circulating blood is evaluated for relative VEcadherin mRNA expression, it has less expression than control mouse embryonic fibroblasts ( Figure S4C ). This further suggests that previously reported VE-cadherin protein expression in peripheral blood (Taoudi et al., 2005) is likely historical following an endothelial origin and not due to concurrent gene expression.
Other Endothelial Populations Are Capable of Hematopoiesis
While our in vivo induction strategy was capable of focused AGM labeling in lieu of the vitelline and umbilical arteries, the placental vasculature was also labeled within our defined tamoxifen window ( Figure S5A ). As the placental vasculature has recently been suggested to be a source of hematopoiesis (Alvarez-Silva et al., 2003; Rhodes et al., 2008) , we undertook a similar in vitro strategy of induction (Supplemental Experimental Procedures). During this period, while not as robust as the AGM (Figure 5B ), our data support the concept that the placental endothelium is also a source of hematopoietic cells ( Figure S5B ).
The early yolk sac (E7-7.5) has also been shown to produce hematopoietic populations that express VE-cadherin with possible definitive potential (Samokhvalov et al., 2007; Yokomizo et al., 2007) . Our lineage tracing strategy avoids labeling this early population. Later in gestation, the yolk sac has been shown to contain definitive HSCs that are not thought to arise in situ (Cumano et al., 2001) . Interestingly, using organotypic in vitro induction of the yolk sac at E10.5, E11.5, and E12.5, we observed endothelial-derived hematopoietic cell emergence ( Figure S6 ). These results are in agreement with earlier studies that demonstrated the hematopoietic potential of yolk sac side population cells from E9.5 to E11.5 (Nadin et al., 2003) .
The AGM Hematopoietic Population Is Endothelial Derived
The ability to lineage trace the VE-cadherin AGM population results from the fact that AGM hematopoietic cells are not only in contact with the endothelium, which canonically expresses VEcadherin, but also that the hematopoietic cells retain reporter activity. This relationship, along with our in vitro induction studies, suggests the emergence of hematopoietic cells from the endothelium. However, there also exists evidence that the underlying mesenchyme of the AGM region may also give rise to HSCs (Bertrand et al., 2005) . To address this issue, we assayed various ''mesenchymal/smooth muscle'' Cre lines that demonstrate a spectrum of Cre expression. The spectrum reflects the complexity of vascular smooth muscle origins (reviewed in Majesky, 2007) . During midgestation, the undifferentiated mesenchyme of the aorta has recently been shown to contain at least two separate mesenchymal populations. The first originates from a splanchnic lateral plate mesoderm and is later replaced by sclerotomal-derived mesoderm (Wiegreffe et al., 2007; Pouget et al., 2008; Wasteson et al., 2008) .
Our initial studies focused on both the constitutive and tamoxifen-inducible smooth muscle 22 a promoter (SM22a) Cre recombinase lines (Kuhbandner et al., 2000; Holtwick et al., 2002) . SM22a is expressed in adult visceral and vascular smooth muscle, and temporarily in embryonic cardiac and somitic mesoderm (Li et al., 1996; Zhang et al., 2001 ). SM22a expression is thought to represent differentiated smooth muscle phenotypes later in development and in the adult (Li et al., 1996; Wasteson et al., 2008) . However, SM22a is also noted in mesenchymal populations surrounding the aorta as early as E9.0 (Li et al., 1996) . During AGM development, the constitutive SM22a Cre labeled both the underlying mesenchyme and the endothelium, resulting in longterm labeling of both the adult aortic endothelium and adult bone marrow cells ( Figure 6A ). This finding was confirmed in a separate SM22a Cre recombinase line obtained from our collaborators and was likely a result of labeling early aortic mesodermal lineages known to have the capacity to differentiate into endothelium (Wasteson et al., 2008) . To investigate whether the endothelial (and subsequent hematopoietic) labeling could be avoided by tracking later SM22a mesodermal lineages, we investigated a tamoxifen-inducible SM22a Cre line. Timed induction at E9.5 demonstrates a decrease in endothelial b-gal expression but still resulted in hematopoietic labeling ( Figure 6A ). The phenomenon is developmentally related, as induction in the adult does not result in endothelial or hematopoietic labeling ( Figure S7A ). Therefore, it appears that SM22a is expressed in both early and late mesodermal populations that reside in the subaortic floor. However, the former contributes to the endothelium of this region and thus precludes the ability to distinguish the properties of the latter. This may also be the case for other endothelial niches, as the yolk sac and placental endothelium appear labeled in the SM22a lineage ( Figure S7B ). It should be noted that while SM22a Cre is expressed in the aortic endothelium, it is not detected in the endothelial cells of other adult vascular beds ( Figure 6C ).
Myocardin, a transcriptional cofactor in smooth muscle cell differentiation, is noted to be predominately expressed in cardiac and smooth muscle cells (Wang et al., 2001 ). However, developmentally, it is also a marker of somitic mesoderm, as myocardin Cre expression is found in dermamyotome and sclerotome populations (Long et al., 2007) . The latter sclerotome population is implicated as a progenitor to the ''replacement'' vascular smooth muscle cells of the aorta (Wasteson et al., 2008) . As a result, To restrict SM22a Cre labeling to a period during AGM hematopoiesis, a tamoxifen-inducible SM22a Cre was employed and induced at E9.5. While the mesenchymal contribution to the endothelium was decreased in the AGM (E11.5), there remained a population of labeled endothelium and subsequent hematopoietic cells (10.77%) in the adult. (B) Myocardin Cre crossed to a R26R lacZ reporter line demonstrates labeling of the AGM mesenchyme at E11.5, without contribution to the AGM or adult aortic endothelium, and absence of any hematopoietic contribution to adult bone marrow (0.58% with 1.36% WT background in FACS-gal assay). (C) Whole-mount SM22a Cre and VE-cadherin Cre embryos at E10.5 demonstrate similar b-gal staining pattern in the dorsal aorta (arrowheads), but not in the intersomitic or surface vessels (arrows). When the two Cre lines are compared in adult vascular beds, the smooth muscle layers are labeled in the SM22a line (arrows), but not in the VE-cadherin line (arrowheads). In contrast, the endothelial layer is labeled in the VE-cadherin Cre (arrows), but not the SM22a Cre (arrowheads). (A-C) b-gal activity depicted in blue, nuclear counterstain in red. Scale bars, 50 mm, unless otherwise specified.
myocardin Cre is notably expressed in AGM subaortic mesenchyme, but not endothelium ( Figure 6B ). When followed into adulthood, the absence of endothelial labeling results in lack of b-gal hematopoietic expression ( Figure 6B) . Thus, the subaortic mesenchyme is unable to directly give rise to HSCs, and only through an endothelial intermediate can hematopoiesis occur.
DISCUSSION
The time of onset and anatomical location of definitive hematopoiesis have been studied with equal parts rigor and contentiousness. Many approaches have been employed, which have included physically separating areas of hematopoiesis and maintaining them in vitro. While the information gained from these studies has been invaluable, questions remained as to the potential of the studied populations in vivo, the cell types responsible for definitive hematopoiesis, and whether a distinct intraembryonic population could autonomously give rise to adult lineages. Lineage tracing allows specific cell populations to be mapped in vivo, and in the current study has demonstrated that the VE-cadherin lineage of the AGM (and possibly the placenta and yolk sac) is capable of long-term, multilineage adult hematopoiesis. In addition, the induction of VE-cadherin promoterdriven Cre activity ex vivo demonstrates that while HSCs in the circulation and fetal liver may express VE-cadherin protein (Kim et al., 2005; Taoudi et al., 2005) , these populations do not demonstrate activity of the VE-cadherin promoter. The VE-cadherin protein expression within these populations is therefore a likely consequence of their descent from the endothelium, which constitutively expresses both the VE-cadherin promoter and protein (Breier et al., 1996) .
The debate as to which cell type is responsible for AGM HSC emergence (endothelium or mesenchyme) lies in the diverse characteristics of the region. Runx1, a transcription factor required for definitive hematopoiesis, is broadly expressed in AGM hematopoietic cells, endothelium, and underlying mesenchyme ( Figure 7A ) (Wang et al., 1996; North et al., 1999; Cai et al., 2000) . While many cell-surface proteins are shared between the endothelium and their attached hematopoietic cells in this region (including PECAM, CD34, and VE-cadherin) (North et al., 2002; Bollerot et al., 2005) , hematopoietic markers (AA4.1, GATA-3) are also expressed in mesenchymal subaortic patches (Bertrand et al., 2005) . Unfortunately, the timing and sequence of HSC cell marker expression as cells emerge from this region is not known, making it difficult to conclude whether the subaortic patches are supporting or giving rise to HSCs. However, when the critical Runx1 gene is ablated in endothelium and accompanying hematopoietic cells, definitive hematopoiesis is halted (Li et al., 2006) .
Our ability to selectively lineage trace both the endothelium and mesenchyme separately allowed us to demonstrate that indeed the endothelium is responsible for HSC emergence in this region ( Figure 7A ). However, the task of selectively labeling the underlying mesenchyme, in lieu of the endothelium, was more difficult than initially anticipated. SM22a, a cytoskeletal protein expressed exclusively in visceral and vascular smooth muscle during postnatal development, also labels early aortic mesoderm in the embryo (Zhang et al., 2001) . When indelibly tagged using a constitutive or an inducible SM22a Cre, this mesoderm is found to contribute to the endothelial floor of the dorsal aorta. This correlates with recent data of aortic floor formation in both avian and murine systems (Pouget et al., 2006; Wiegreffe et al., 2007; Wasteson et al., 2008) . The mesenchymal floor of the AGM region is shown to be transiently formed by lateral plate mesoderm capable of contribution to the aortic endothelium (Wasteson et al., 2008) . The mesenchymal population is then replaced by a second population, derived from sclerotomal mesoderm, that migrates from the dorsal and lateral walls to the ventral side of the aorta (Wiegreffe et al., 2007; Pouget et al., 2008; Wasteson et al., 2008) . This second wave migration of mesenchymal cells closely mirrors the developmental pattern of myocardin Cre lineages in the embryonic aorta (Long et al., 2007) . As evidenced here, in the myocardin Cre line, this second population does not contribute to the endothelium. Therefore, SM22a Cre labels both early and late mesodermal populations, while myocardin Cre labels the later permanent population, thus enabling the tracing of early and late populations and their subsequent hematopoietic potential. By doing so, we have demonstrated that only the early mesenchymal population, which contributes to the aortic floor endothelium (and placental and yolk sac vasculature, Figure S7 ), has the capacity for hematopoiesis and does so via an endothelial intermediate ( Figure 7B ).
The fact that the endothelium responsible for hematopoiesis, e.g., hemogenic endothelium, appears to develop from a transient early mesenchymal lineage imparts a specialization to the endothelium. Yet, its hematopoietic capacity is fleeting, much like the initial population of the underlying AGM mesenchyme. It may be that the manifestation of hemogenic endothelium requires not only specified endothelium but also a specialized niche within the underlying mesenchyme. The complex orchestration of signaling between AGM mesenchyme and endothelium remains to be dissected. However, our data provide in vivo physiologic evidence that endothelium is responsible for stem cell emergence within the AGM region, and furthermore that this endothelium is derived from a transient mesenchymal population.
EXPERIMENTAL PROCEDURES Animals
Animals were housed and animal protocols conducted in accordance with University of California, Los Angeles (UCLA) Animal Research Committee guidelines. VE-cadherin Cre and inducible VE-cadherin Cre mice, described elsewhere Monvoisin et al., 2006) , were crossed to R26R Cre reporter lines with lacZ reporter (Soriano, 1999) and separately EYFP reporter (Srinivas et al., 2001 ). SM22a Cre (Holtwick et al., 2002) was obtained from Jackson laboratories, and tamoxifen-inducible SM22a Cre (Kuhbandner et al., 2000) was a generous gift from Robert Feil (Institute of Pharmacology and Toxicology, Germany). An additional SM22a Cre/R26R lacZ line was provided by Michelle Tallquist (UT Southwestern, Dallas, TX). The myocardin Cre/ R26R lacZ line (Long et al., 2007) was provided by Eric Olson (UT Southwestern, Dallas, TX). The Runx1-lacZ (North et al., 1999) reporter line was provided by Nancy Speck (Dartmouth Medical School, Hanover, NH). Pregnancies were dated by observance of a vaginal plug (gestation day 0.5 on day of plug). Tamoxifen (ICN) was prepared as described , and pregnant females were injected with 1 mg (100 ml) i.p. at E9.5 (or E8.5 for AGM timing experiments). Embryos that were followed to adulthood underwent Cesarean section if the mother was unable to give birth naturally. The pups were then fostered with other females. A minimum of three litters was investigated for all VE-cadherin Cre (constitutive and inducible) time points, n = 12-13 adults. For SM22a Cre and myocardin Cre lines, n = 2-3 litters, n = 2-5 for adults, and iSM22Cre adult n = 1.
b-Gal Activity and Immunohistochemistry b-gal staining and histology were carried out as previously described . Vibratome sections (400 mm) of E13.5-E14.5 embryos were fixed in 2% paraformaldehyde, then incubated with 1:100 VE-cadherin monoclonal rat anti-mouse antibody BV13/4 (generous gift from ImClone Systems, Inc.) and 1:200 Cy3 secondary antibody (Jackson ImmunoResearch). For myocardin Cre sections, embryos were fixed in 2% formaldehyde/0.2% glutaraldehyde and embedded in OCT. Ten micron sections were then stained in X-gal following standard protocols.
Flow Cytometry FACS analysis of b-gal was carried out as described . Tissues underwent mechanical dissociation by pipetting to single-cell suspension. Cells were analyzed on a FACSCalibur with the following monoclonal antibodies: Sca-1-PE (E13-161.7), c-kit-APC (2B8), AA4.1-PE, CD34-APC (RAM34), TER119-APC, CD71-PE (C2), Mac1-APC (M1/70), Gr-1-PE (8C5), CD3-APC (2C11), CD4-PE (GK1.5), CD8-APC (53-6.7), B220-PE (62B), CD45-APC (F11), PECAM-1-PE (MEC 13.3), and 7-AAD (7-amino-actinomycin D) for viability. All monoclonal antibodies, their appropriate isotype controls, and 7-AAD were purchased from BD Pharmingen.
Organ Culture and Hematopoietic Assays
Fetal livers from E10.5, E11.5, and E12.5 (and E11.5 AGM) were dissected and cultured for 24 hr on 40 mm filters at an air-liquid interface, as described (Medvinsky and Dzierzak, 1996) , in myelocult media (Stem Cell Technologies), supplemented with 10 À6 M hydrocortisone (Stem Cell Technologies) and 10 mM of 4OHT (Sigma). A subset of cultured organs underwent b-gal staining (n = 3), while the rest were mechanically dissociated and plated at 4 3 10 3 cells/ml in Methocult M3434 methylcellulose media (Stem Cell Technologies) for approximately 1 week (n = 3). After colonies were expanded, cells were removed from culture, resuspended, and X-gal stained. Alternatively, for EYFP lines, cells were stained for CD45-APC and 7-AAD and analyzed for EYFP expression by FACS (gated on CD45+ and 7-AADÀ).
In Vitro 4OHT Induction of Peripheral Blood Inducible VE-cadherin Cre crossed to EYFP R26R litters of E10.5, E11.0-11.5, and E12.5 (pooled separately, n = 3 litters each) were bled in warm PBS after removal of embryos from their respective yolk sacs and placentas. The peripheral blood cells were pelleted and resuspended in the same media used in the fetal liver assays (above) with 10 mM of 4OHT (Sigma) for 24 hr. The cells were then stained for CD45-APC and 7-AAD and analyzed for EYFP expression by FACS (gated on CD45+ and 7-AADÀ). Alternatively, the AGMs from the same litter at E11.0 were cultured on 40 mm filters (as described above) for 24 hr in 4OHT and then pooled and analyzed for EYFP expression by FACS (gated for hematopoietic cells, CD45+ and 7-AADÀ; or endothelium, PECAM+CD45À and 7-AADÀ).
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